Femasys Inc
femasys.comWhat Do They Do?
Sells in-office fertility and diagnostic products, permanent birth-control systems, and tissue-sampling devices to gynecologists and fertility specialists.
10-K for FY2025, filed Mar 31, 2026We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected…View ↗
FemBloc® permanent birth control is a revolutionary first-in-class non-surgical solution, which involves minimally-invasive placement of a…View ↗
FemaSeed – Our Artificial Insemination Therapeutic Solution, FemVue – Our Companion Diagnostic for Tubal Evaluation and FemSperm – Our…View ↗
FemBloc – Our Permanent Birth Control Solution and FemChec – Our Companion Diagnostic for Tubal Occlusion Confirmation. FemBloc is our…View ↗
Additional Women’s Health Solutions. Our FemCerv product, an endocervical tissue sampler for cervical cancer diagnosis, is U.S. FDA-cleared…View ↗
With the 510(k) clearance from the FDA and regulatory approval from Europe, UK, Canada and Israel for FemaSeed, we have recruited a direct…View ↗
How Do They Make Money?
It sells products to medical centers and international distributors, with sales counted when goods ship.
$2.3M
-
10-K for FY2025, filed Mar 31, 2026
$2.3M ↗
Who Are Their Customers?
In the U.S., medical centers and healthcare practitioner offices are served primarily by its direct commercial team; in selected international markets, distributors sell its products.
10-K for FY2025, filed Mar 31, 2026We sell our product to medical centers, including healthcare practitioner offices, primarily through our direct commercial team in the…View ↗
10-K for FY2025, filed Mar 31, 2026
The Company generates revenue from sales directly to U.S. customers and to the Company’s international distributors with all prices in U.S.…View ↗
Do Revenues Turn Into Profits?
No. It lost $18.6M in FY2025.
10-K for FY2025, filed Mar 31, 2026
−$17.6MView ↗
10-K for FY2025, filed Mar 31, 2026
−$18.6MView ↗
10-K for FY2025, filed Mar 31, 2026
−$19.2MView ↗
How Are They Changing?
FemaSeed commercialization
FemaSeed has moved from a product candidate in clinical testing to a cleared and marketed fertility treatment, with commercial sales alongside FemVue.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 31, 2026FemaSeed – Our Artificial Insemination Solution. Our artificial insemination solution in development includes our proprietary FemaSeed…View ↗
FemaSeed – Our Artificial Insemination Therapeutic Solution, FemVue – Our Companion Diagnostic for Tubal Evaluation and FemSperm – Our…View ↗
In April 2021 we received an IDE approval from the FDA that allowed us to initiate a pivotal trial for the FemaSeed device. The first…View ↗
We sell our product to medical centers, including healthcare practitioner offices, primarily through our direct commercial team in the…View ↗
FemBloc's international path
FemBloc has moved from development toward international commercialization, with approvals and distribution partnerships outside the U.S.; its U.S. path still depends on clinical development.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 31, 2026FemBloc – Our Permanent Birth Control Solution. Our permanent birth control solution in development includes our proprietary FemBloc…View ↗
In March 2025, we announced CE mark certification under EU MDR as the first regulatory approval in the world for the FemBloc delivery…View ↗
Who Do They Compete With?
Competes with Cook Medical, Cooper Surgical, MedGyn Products, Rocket Medical, Dysis Medical, and Guided Therapeutics
10-K for FY2025, filed Mar 31, 2026With respect to our artificial insemination solution, we expect to compete with IUI, IVF/ ICSI and fertility-enhancing pharmaceuticals…View ↗
Loading...
